These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18042509)

  • 1. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090.
    Evans SR; Yeh TM; Sacktor N; Clifford DB; Simpson D; Miller EN; Ellis RJ; Valcour V; Marra CM; Millar L; Schifitto G;
    HIV Clin Trials; 2007; 8(6):437-46. PubMed ID: 18042509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
    Schifitto G; Zhang J; Evans SR; Sacktor N; Simpson D; Millar LL; Hung VL; Miller EN; Smith E; Ellis RJ; Valcour V; Singer E; Marra CM; Kolson D; Weihe J; Remmel R; Katzenstein D; Clifford DB;
    Neurology; 2007 Sep; 69(13):1314-21. PubMed ID: 17652642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline and oxidative stress in HIV-associated cognitive impairment.
    Schifitto G; Yiannoutsos CT; Ernst T; Navia BA; Nath A; Sacktor N; Anderson C; Marra CM; Clifford DB;
    Neurology; 2009 Dec; 73(23):1975-81. PubMed ID: 19890073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
    Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
    AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD
    J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.
    Muñoz-Moreno JA; Prats A; Moltó J; Garolera M; Pérez-Álvarez N; Díez-Quevedo C; Miranda C; Fumaz CR; Ferrer MJ; Clotet B;
    PLoS One; 2017; 12(8):e0182547. PubMed ID: 28854283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
    Sacktor N; Schifitto G; McDermott MP; Marder K; McArthur JC; Kieburtz K
    Neurology; 2000 Jan; 54(1):233-5. PubMed ID: 10636157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
    Elkashef A; Fudala PJ; Gorgon L; Li SH; Kahn R; Chiang N; Vocci F; Collins J; Jones K; Boardman K; Sather M
    Drug Alcohol Depend; 2006 Dec; 85(3):191-7. PubMed ID: 16730924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial.
    Sacktor N; Miyahara S; Deng L; Evans S; Schifitto G; Cohen BA; Paul R; Robertson K; Jarocki B; Scarsi K; Coombs RW; Zink MC; Nath A; Smith E; Ellis RJ; Singer E; Weihe J; McCarthy S; Hosey L; Clifford DB;
    Neurology; 2011 Sep; 77(12):1135-42. PubMed ID: 21900636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine for AIDS dementia complex: open-label report of ACTG 301.
    Zhao Y; Navia BA; Marra CM; Singer EJ; Chang L; Berger J; Ellis RJ; Kolson DL; Simpson D; Miller EN; Lipton SA; Evans SR; Schifitto G;
    HIV Clin Trials; 2010; 11(1):59-67. PubMed ID: 20400412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA; Amsterdam JD
    Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
    Neurology; 1998 Mar; 50(3):645-51. PubMed ID: 9521250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical appraisal of the selegiline transdermal system for major depressive disorder.
    Bied AM; Kim J; Schwartz TL
    Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
    Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD
    J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS; Amsterdam JD
    J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline transdermal system (STS) as an aid for smoking cessation.
    Kahn R; Gorgon L; Jones K; McSherry F; Glover ED; Anthenelli RM; Jackson T; Williams J; Murtaugh C; Montoya I; Yu E; Elkashef A
    Nicotine Tob Res; 2012 Mar; 14(3):377-82. PubMed ID: 21846661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
    Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
    Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.